Sochacka Małgorzata, Giebułtowicz Joanna, Remiszewska Małgorzata, Suchocki Piotr, Wroczyński Piotr
Department of Bioanalysis and Drugs Analysis, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.
Department of Bioanalysis and Drugs Analysis, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.
Pharmacol Rep. 2014 Apr;66(2):301-10. doi: 10.1016/j.pharep.2013.10.004. Epub 2014 Mar 4.
Selol is a novel organoselenium Se(IV) compound. It reveals lower potential of toxicity than sodium selenite and does not exhibit mutagenic activity. Its antioxidant and anticancer properties including overcoming cancer cell resistance to standard therapy of the drug were proven. This is the first publication describing the influence of Selol 5% on the activity of blood antioxidant status in vivo.
We investigated the influence of Selol 5% short-term (24h) and long-term (28 days) administration on the activity of antioxidant enzymes, including the main selenoenzymes, in healthy mice plasma and erythrocytes. Plasma oxygen radical absorbance capacity value (ORAC) and the concentration of malonyldialdehyde (MDA) in plasma as a biomarker of oxidative stress as well as the value of selenium (Se) concentration in erythrocytes were shown.
A significant increase of the selenium dependent glutathione peroxidase (Se-GSHPx) activity in plasma and erythrocytes, plasma selenoprotein P concentration, ORAC values, and Se concentration were observed during long-term supplementation as well as after Selol 5% single-dose administration, with two distinct increases of activity a few hours after the beginning of the experiment and before its end. We found a decreased thioredoxin reductase (THRR) activity and an increased MDA level during Selol 5% long-term supplementation. Glutathione S-transferase activity (GST) remained unchanged.
Selol 5% supplementation in vivo affects the selenoenzymes activities as well as the antioxidant status of plasma and erythrocytes. Selol 5% is an inhibitor of thioredoxin reductase activity, which can be important in anticancer therapy.
硒乐是一种新型有机硒（IV）化合物。它的毒性潜力低于亚硒酸钠，且不具有诱变活性。其抗氧化和抗癌特性，包括克服癌细胞对该药物标准疗法的耐药性，已得到证实。这是第一篇描述5%硒乐对体内血液抗氧化状态活性影响的出版物。
我们研究了5%硒乐短期（24小时）和长期（28天）给药对健康小鼠血浆和红细胞中抗氧化酶活性的影响，包括主要的含硒酶。展示了血浆氧自由基吸收能力值（ORAC）、作为氧化应激生物标志物的血浆中丙二醛（MDA）浓度以及红细胞中硒（Se）浓度的值。
在长期补充以及5%硒乐单剂量给药后，观察到血浆和红细胞中硒依赖性谷胱甘肽过氧化物酶（Se-GSHPx）活性、血浆硒蛋白P浓度、ORAC值和硒浓度显著增加，在实验开始后几小时和结束前活性有两个明显的增加。我们发现5%硒乐长期补充期间硫氧还蛋白还原酶（THRR）活性降低，MDA水平升高。谷胱甘肽S-转移酶活性（GST）保持不变。
体内补充5%硒乐会影响含硒酶活性以及血浆和红细胞的抗氧化状态。5%硒乐是硫氧还蛋白还原酶活性的抑制剂，这在抗癌治疗中可能很重要。
